Upadacitinib clinical trials
Also written RINVOQ and ABT-494.
How each study uses upadacitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the upadacitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 16 Aug 2019 · RINVOQ · NDA 211675 (FDA, Drugs@FDA)
- European Union
- 16 Dec 2019 · Rinvoq · EMEA/H/C/004760 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
97 studies that test it; most in 2026 (19); 1 more planned to start later
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 7 |
| 2017 | 6 |
| 2018 | 8 |
| 2019 | 7 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 11 |
| 2024 | 13 |
| 2025 | 10 |
| 2026 | 19 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 64 · Other 34
AbbVie (60) · Sixth Affiliated Hospital, Sun Yat-sen University (5) · Peking University People's Hospital (3) · University of California, San Francisco (2) · CARE ARTHRITIS LTD. (2) · Berinstein, Jeffrey (2) · Tianjin Medical University (1) · Peking Union Medical College (1)
Often tested with
Tested in the same studies.
Tofacitinib (5) · Secukinumab (4) · Elsubrutinib (4) · Adalimumab (3) · ABBV-722 (3) · Baricitinib (3) · Ixekizumab (3) · Ustekinumab (3)
Related medicines
As reviewed, each with the page that says it.
- One of JAK inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 18, 8 in phase 3
Studies that test upadacitinib, phase 3 first.
- Nov 2026A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabPhase 3 · AbbVie
- Dec 2026Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug StudyPhase 3 · Douglas D. Fraser
- Dec 2026Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled StudyPhase 3 · Sixth Affiliated Hospital, Sun Yat-sen University
- Jan 2027Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic DermatitisPhase 3 · AbbVie
- Mar 2027Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus ErythematosusPhase 3 · AbbVie
- May 2027Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative ColitisPhase 3 · McMaster University
- Jul 2027A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)Phase 3 · AbbVie
- Sep 2027A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433Phase 3 · AbbVie
- Dec 2026A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult VolunteersPhase 1 · AbbVie
- Dec 2026Therapeutic Effect of Upadacitinib in Primary Sjögren's SyndromePhase 2 · Peking University People's Hospital
Studies
Open first, then newest update. How each study uses upadacitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 98
- Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating MutationsNot yet recruitingPhase 1/2Lisa SatterNCT07670156Written as Upadacitinib
- A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further.Not yet recruitingPhase 2/3AbbVieNCT07933211Written as Upadacitinib
- Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid ArthritisNot yet recruitingPhase 2AbbVieNCT07904754Written as Upadacitinib
- Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance DoseNot yet recruitingPhase 4Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesNCT07700446Written as Upadacitinib
- A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental VitiligoNot yet recruitingPhase 3AbbVieNCT07896434Written as Upadacitinib
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia AreataRecruitingPhase 3AbbVieNCT07772492Written as Upadacitinib
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia AreataRecruitingPhase 3AbbVieNCT06012240Written as Upadacitinib
- A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial SpondyloarthritisNot yet recruitingPhase 4The University of Texas Health Science Center, HoustonNCT07770646Written as Upadacitinib (JAKi)
- Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug StudyRecruitingPhase 3Douglas D. FraserNCT06928272Written as Upadacitinib
- A Trial of Upadacitinib for Non-responsive Eosinophilic EsophagitisRecruitingPhase 2University of North Carolina, Chapel HillNCT07588568Written as Upadacitinib 30mg Dose
- Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study.RecruitingPhase 2Centre Hospitalier Universitaire de NiceNCT07492251Written as Upadacitinib
- A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult VolunteersRecruitingPhase 1AbbVieNCT07843693Written as Upadacitinib
- Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative ColitisNot yet recruitingPhase 4University of California, San FranciscoNCT07502339Written as Upadacitinib
- Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.RecruitingPhase 3AbbVieNCT05609630Written as Upadacitinib
- Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative ColitisRecruitingPhase 4Berinstein, JeffreyNCT05867329Written as Upadacitinib Extended Release Oral Tablet
- JAK Inhibitor Dose TAPering Strategy StudyRecruitingPhase 4University Hospital, ToulouseNCT06687551Written as Upadacitinib 15 MG
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as Upadacitinib
- The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe ItchingNot yet recruitingPhase 2RenJi HospitalNCT07678645Written as Upadacitinib 15 MG
- Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis(UPFRONT)RecruitingPhase 4Yongquan ShiNCT07546097Written as Upadacitinib
- TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal ResponseRecruitingPhase 4Sixth Affiliated Hospital, Sun Yat-sen UniversityNCT07510191Written as Upadacitinib
See all 98 studies that test upadacitinib →
Given beside what is tested · 3 — upadacitinib is usual care or a partner of the new treatment
- A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's DiseaseRecruitingPhase 3TakedaNCT06227910Written as Upadacitinib
- A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to MethotrexateActive, not recruitingPhase 3AbbVieNCT02629159Written as Upadacitinib
- A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDsCompletedPhase 3AbbVieNCT03086343Written as Upadacitinib
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered3
- A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further.Nov 12, 2026NCT07933211
- Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid ArthritisOct 29, 2026NCT07904754
- A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental VitiligoOct 27, 2026NCT07896434
Codes
What other systems call upadacitinib · ClinicalTrials.gg INT000588
- MeSH (NLM) C000613732upadacitinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 4RA0KN46E0UPADACITINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2196092Confirmed FDA, Wikidata
- Wikidata Q27074125upadacitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152802UpadacitinibOne source FDA
- DrugBank DB15091One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000613732 | upadacitinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 4RA0KN46E0 | UPADACITINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2196092 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27074125 | upadacitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152802 | Upadacitinib | One source FDA |
| DrugBank | DB15091 | — | One source Wikidata |
Also registered as upadacitinib hemihydrate (UNII NEW4DV02U5).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.